Total Payments
$755,143
2024 Payments
$23,234
Companies
38
Transactions
181
Medicare Patients
39,700
Medicare Billing
$2.1M
Payment Breakdown by Category
Research$752,036 (99.6%)
Food & Beverage$2,939 (0.4%)
Consulting$150.00 (0.0%)
Education$18.76 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $752,036 | 9 | 99.6% |
| Food and Beverage | $2,939 | 167 | 0.4% |
| Consulting Fee | $150.00 | 1 | 0.0% |
| Education | $18.76 | 4 | 0.0% |
Payments by Type
Research
$752,036
9 transactions
General
$3,107
172 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $752,036 | 9 | $0 (2024) |
| ABBVIE INC. | $352.78 | 25 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $286.12 | 12 | $0 (2021) |
| Abbott Laboratories | $283.41 | 7 | $0 (2022) |
| Dexcom, Inc. | $225.66 | 11 | $0 (2024) |
| Amgen Inc. | $156.68 | 9 | $0 (2024) |
| Novo Nordisk Inc | $150.45 | 9 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $150.07 | 9 | $0 (2022) |
| Allergan, Inc. | $150.05 | 12 | $0 (2020) |
| Alkermes, Inc. | $150.00 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $23,234 | 24 | Eli Lilly and Company ($22,772) |
| 2023 | $6,905 | 14 | Eli Lilly and Company ($6,644) |
| 2022 | $133,239 | 28 | Eli Lilly and Company ($132,931) |
| 2021 | $590,242 | 44 | Eli Lilly and Company ($589,689) |
| 2020 | $262.23 | 19 | Allergan, Inc. ($119.28) |
| 2019 | $360.20 | 20 | Janssen Pharmaceuticals, Inc ($58.10) |
| 2018 | $438.13 | 18 | Abbott Laboratories ($159.13) |
| 2017 | $462.20 | 14 | AstraZeneca Pharmaceuticals LP ($157.17) |
All Payment Transactions
181 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $19.34 | General |
| Category: Endocrinology | ||||||
| 12/10/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $19.43 | General |
| Category: Endocrinology | ||||||
| 12/05/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $22.02 | General |
| Category: Endocrinology | ||||||
| 11/19/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $22,772.00 | Research |
| Study: A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | ||||||
| 11/14/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $15.47 | General |
| Category: Inflammation | ||||||
| 11/12/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $17.32 | General |
| 11/01/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $15.76 | General |
| Category: Inflammation | ||||||
| 09/25/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $19.22 | General |
| Category: Endocrinology | ||||||
| 09/12/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $16.22 | General |
| Category: Diabetes | ||||||
| 09/09/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $24.34 | General |
| Category: Endocrinology | ||||||
| 08/06/2024 | Medtronic, Inc. | COREVALVE EVOLUT R (Device) | Food and Beverage | In-kind items and services | $14.41 | General |
| Category: Transcatheter Valve Systems | ||||||
| 07/25/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Endocrinology | ||||||
| 07/25/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $15.67 | General |
| Category: Inflammation | ||||||
| 06/28/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $22.28 | General |
| Category: Inflammation | ||||||
| 06/14/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $20.73 | General |
| Category: Endocrinology | ||||||
| 06/13/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $23.78 | General |
| Category: Biological | ||||||
| 06/06/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $23.24 | General |
| Category: Endocrinology | ||||||
| 05/22/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $20.42 | General |
| Category: Endocrinology | ||||||
| 05/17/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $26.80 | General |
| Category: Inflammation | ||||||
| 05/07/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $23.40 | General |
| Category: Biological | ||||||
| 04/30/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $24.42 | General |
| Category: NEUROLOGY | ||||||
| 04/11/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $18.61 | General |
| Category: Endocrinology | ||||||
| 02/26/2024 | Medtronic, Inc. | VENASEAL (Device) | Food and Beverage | In-kind items and services | $19.56 | General |
| Category: EndoVenous Therapies | ||||||
| 01/24/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $14.49 | General |
| Category: Inflammation | ||||||
| 11/14/2023 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $17.85 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) | Eli Lilly and Company | $483,789 | 2 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $155,715 | 4 |
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | Eli Lilly and Company | $105,889 | 2 |
| A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | Eli Lilly and Company | $6,644 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 42 | 11,235 | 80,882 | $1.6M | $526,002 |
| 2022 | 50 | 9,941 | 115,576 | $1.7M | $574,171 |
| 2021 | 58 | 10,544 | 100,690 | $1.9M | $657,149 |
| 2020 | 48 | 7,980 | 48,746 | $1.3M | $381,563 |
Total Patients
39,700
Total Services
345,894
Medicare Billing
$2.1M
Procedure Codes
198
All Medicare Procedures & Services
198 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 1,000 | 2,354 | $597,916 | $191,336 | 32.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 333 | 554 | $188,360 | $66,261 | 35.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 350 | 350 | $93,100 | $43,129 | 46.3% |
| 82306 | Vitamin d-3 level | Office | 2023 | 599 | 776 | $72,168 | $22,462 | 31.1% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 91 | 99 | $54,351 | $20,442 | 37.6% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 690 | 983 | $57,014 | $16,180 | 28.4% |
| 84481 | Thyroid hormone, t3 measurement, free | Office | 2023 | 678 | 972 | $56,376 | $16,135 | 28.6% |
| 0241U | Respiratory infectious agent detection by rna for severe acute respiratory syndrome coronavirus 2 (covid 19), influenza a, influenza b, and respiratory syncytial virus, upper respiratory specimen, each reported as detected or not detected | Office | 2023 | 96 | 107 | $21,400 | $14,956 | 69.9% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 667 | 909 | $41,814 | $11,914 | 28.5% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 720 | 1,104 | $39,744 | $11,417 | 28.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 776 | 1,330 | $26,600 | $11,164 | 42.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 742 | 1,158 | $31,266 | $8,805 | 28.2% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 646 | 922 | $30,426 | $8,777 | 28.8% |
| 84439 | Thyroxine (thyroid chemical), free | Office | 2023 | 675 | 958 | $29,698 | $8,469 | 28.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 120 | 138 | $23,874 | $7,830 | 32.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 341 | 825 | $49,500 | $7,157 | 14.5% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 41 | 46 | $17,848 | $7,060 | 39.6% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 351 | 351 | $15,093 | $6,157 | 40.8% |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | Office | 2023 | 337 | 337 | $14,491 | $5,910 | 40.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 63 | 63 | $24,696 | $5,538 | 22.4% |
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | Office | 2023 | 219 | 219 | $13,359 | $5,402 | 40.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 33 | 33 | $16,038 | $4,545 | 28.3% |
| 84403 | Testosterone (hormone) level, total | Office | 2023 | 142 | 177 | $15,753 | $4,476 | 28.4% |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | Office | 2023 | 202 | 202 | $12,726 | $3,822 | 30.0% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2023 | 20 | 20 | $7,800 | $3,027 | 38.8% |
About Dr. Robert Laningham, MD
Dr. Robert Laningham, MD is a Family Medicine healthcare provider based in Conroe, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1700973682.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Laningham, MD has received a total of $755,143 in payments from pharmaceutical and medical device companies, with $23,234 received in 2024. These payments were reported across 181 transactions from 38 companies. The most common payment nature is "" ($752,036).
As a Medicare-enrolled provider, Laningham has provided services to 39,700 Medicare beneficiaries, totaling 345,894 services with total Medicare billing of $2.1M. Data is available for 4 years (2020–2023), covering 198 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Conroe, TX
- Active Since 10/10/2006
- Last Updated 04/04/2023
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1700973682
Products in Payments
- UBRELVY (Drug) $252.03
- FARXIGA (Drug) $209.97
- Dexcom G6 Transmitter (Medical Supply) $191.62
- VRAYLAR (Drug) $162.96
- Axium INS DRG IPG (Device) $159.13
- Otezla (Drug) $110.47
- XARELTO (Drug) $108.14
- Veozah (Drug) $92.34
- TRINTELLIX (Drug) $89.50
- TRULICITY (Drug) $74.18
- Orserdu (Drug) $70.86
- Ozempic (Drug) $69.52
- TRELEGY ELLIPTA (Drug) $58.10
- QULIPTA (Drug) $57.07
- Proclaim Family of SCS IPGs (Device) $48.09
- SHINGRIX (Biological) $47.74
- Aimovig (Biological) $46.21
- Trintellix (Drug) $44.50
- ELIQUIS (Drug) $41.52
- SOLIQUA 100/33 (Biological) $41.17
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Conroe
Elena Garcia, Md, MD
Family Medicine — Payments: $20,795
Family Medicine $20,795
Dr. Samson Sheih, M.d, M.D
Family Medicine — Payments: $15,851
Family Medicine $15,851
Kyle Scarborough, Md, MD
Family Medicine — Payments: $15,672
Family Medicine $15,672
Simi Koshy, Md, MD
Family Medicine — Payments: $10,819
Family Medicine $10,819
Dr. Christopher Chapman, Md, MD
Family Medicine — Payments: $10,381
Family Medicine $10,381
Dr. Jack Pieniazek, Do, DO
Family Medicine — Payments: $9,552
Family Medicine $9,552